FibroBiologics (NASDAQ:FBLG) Earns Buy Rating from D. Boral Capital

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They currently have a $16.00 target price on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 target price (up previously from $10.00) on shares of FibroBiologics in a report on Tuesday, August 5th. Four analysts have rated the stock with a Buy rating, According to MarketBeat.com, FibroBiologics has an average rating of “Buy” and an average target price of $13.00.

FibroBiologics Price Performance

Shares of FBLG opened at $0.56 on Wednesday. The company has a 50-day moving average of $0.61 and a two-hundred day moving average of $0.83. The stock has a market cap of $23.66 million, a price-to-earnings ratio of -1.57 and a beta of -0.73. FibroBiologics has a one year low of $0.53 and a one year high of $4.14.

FibroBiologics (NASDAQ:FBLG) last issued its quarterly earnings results on Thursday, July 31st. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Analysts anticipate that FibroBiologics will post -0.53 earnings per share for the current year.

Institutional Investors Weigh In On FibroBiologics

A number of hedge funds and other institutional investors have recently made changes to their positions in FBLG. Raymond James Financial Inc. acquired a new stake in shares of FibroBiologics during the 4th quarter valued at about $37,000. AQR Capital Management LLC bought a new position in FibroBiologics during the first quarter valued at approximately $29,000. Nuveen LLC acquired a new stake in FibroBiologics in the first quarter valued at approximately $31,000. XTX Topco Ltd grew its position in FibroBiologics by 160.0% in the second quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after acquiring an additional 28,276 shares in the last quarter. Finally, Ethos Financial Group LLC increased its stake in shares of FibroBiologics by 100.0% during the 2nd quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock worth $30,000 after purchasing an additional 24,424 shares during the last quarter.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.